Takeda Pharmaceutical Company Limited (BVMF:TAKP34)

Brazil flag Brazil · Delayed Price · Currency is BRL
75.76
0.00 (0.00%)
At close: Dec 4, 2025
-6.14%
Market Cap 242.60B
Revenue (ttm) 159.07B
Net Income (ttm) 1.19B
Shares Out n/a
EPS (ttm) 0.74
PE Ratio 203.68
Forward PE n/a
Dividend 2.96 (4.04%)
Ex-Dividend Date Sep 29, 2025
Volume 4
Average Volume 50
Open 76.10
Previous Close n/a
Day's Range 75.76 - 76.10
52-Week Range 70.80 - 92.01
Beta 0.03
RSI 44.18
Earnings Date Jan 29, 2026

About BVMF:TAKP34

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A... [Read more]

Sector Healthcare
Founded 1781
Employees 47,455
Stock Exchange Brazil Stock Exchange
Ticker Symbol TAKP34
Full Company Profile

Financial Performance

In 2024, BVMF:TAKP34's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY Financial Statements

News

There is no news available yet.